Brown Advisory Inc Arvinas, Inc. Transaction History

Brown Advisory Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $1.03 Million - $1.7 Million	41,963 Added 15.31%	316,138 $8.42 Million
Q1 2024 Apr 24, 2024	BUY	$36.38 - $52.31 $318,106 - $457,398	8,744 Added 3.29%	274,175 $11.3 Million
Q4 2023 Feb 08, 2024	SELL	$14.19 - $42.33 $2.41 Million - $7.2 Million	-170,163 Reduced 39.06%	265,431 $10.9 Million
Q3 2023 Oct 24, 2023	SELL	$19.64 - $28.21 $104,465 - $150,048	-5,319 Reduced 1.21%	435,594 $8.56 Million
Q2 2023 Jul 31, 2023	SELL	$21.73 - $31.43 $548,812 - $793,796	-25,256 Reduced 5.42%	440,913 $10.9 Million
Q1 2023 May 08, 2023	BUY	$26.15 - $37.26 $146,963 - $209,401	5,620 Added 1.22%	466,169 $12.7 Million
Q4 2022 Feb 13, 2023	BUY	$32.47 - $57.24 $1.74 Million - $3.06 Million	53,453 Added 13.13%	460,549 $15.8 Million
Q3 2022 Nov 14, 2022	BUY	$41.87 - $57.99 $4.46 Million - $6.18 Million	106,497 Added 35.43%	407,096 $18.1 Million
Q2 2022 Nov 14, 2022	BUY	$36.01 - $74.24 $443,931 - $915,230	12,328 Added 4.28%	300,599 $12.7 Million
Q2 2022 Aug 02, 2022	BUY	$36.01 - $74.24 $10.4 Million - $21.4 Million	288,271 New	288,271 $12.1 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.